Moderna Inc on Thursday raised its annual forecast for COVID-19 vaccine sales to up to $8 billion on hopes of a boost in the fall season as sales move to a private market in the United States from government contracts, sending its shares up 6% in premarket trading. COVID vaccine makers Moderna and Pfizer are pinning their hopes on private markets sales and strong demand for their new updated shots targeting XBB.1.5 variant to turn around a slump in sales of the products that had bumper growth during the peak of the pandemic. Moderna expects $6 billion to $8 billion in sales from its COVID shots this year, up from its previous forecast of $5 billion, driven by potential U.S. demand for 50 to 100 million doses in the fall season.
Moderna Inc on Thursday
raised its annual forecast for COVID-19 vaccine sales to up to
$8 billion on hopes of a boost in the fall season as sales move
to a private market in the United States from.
Moderna Inc on Wednesday said it submitted a marketing authorisation application for the investigational respiratory syncytial virus vaccine mRNA-1345, with the European Medicines Agency, Swissmedic,.
Moderna submits global regulatory submission for respiratory vaccine | Finance News shareprices.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from shareprices.com Daily Mail and Mail on Sunday newspapers.
By Blake Brittain (Reuters) - Despite the backing of the U.S. government, Moderna Inc on Friday failed to persuade a federal judge it should not have .